Opus Genetics (IRD) EBT Margin (2010 - 2026)

Opus Genetics (IRD) has 8 years of EBT Margin data on file, last reported at 3038.25% in Q1 2026.

• EBT Margin for Q1 2026 came in at 3038.25%, down 285074.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 892.36% (down 46295.0% YoY), and the FY2025 annual result was 349.33%, up 17407.0% from the prior year.
• EBT Margin slipped to 3038.25% in Q1 2026 per IRD's latest filing, from 427.5% in the prior quarter.
• Over five years, EBT Margin peaked at 85.96% in Q4 2022 and troughed at 3038.25% in Q1 2026.
• A 5-year average of 515.69% and a median of 307.39% in 2023 frame the typical range for EBT Margin.
• The sharpest annual moves came in 2025 and 2026: EBT Margin jumped 44083 bps in 2025, then tumbled 285074 bps in 2026.
• A 5-year view of EBT Margin shows it stood at 85.96% in 2022, then sank by 430 bps to 283.68% in 2023, then sank by 188 bps to 816.71% in 2024, then soared by 48 bps to 427.5% in 2025, then sank by 611 bps to 3038.25% in 2026.
• Business Quant data shows IRD's EBT Margin at 3038.25% in Q1 2026, 427.5% in Q4 2025, and 566.87% in Q3 2025.